EUVIMEDDescoperă EUVIMED
CrossrefCard informativ

Efficacy of pembrolizumab in urothelial cancer: A systematic review and meta-analysis

Vinay Eruvuri, Nitish Nichenametla, Monish Konda, Bala Sathvika Duggimpudi, Yethindra Vityala

Bladder · 2025

DOI: 10.14440/bladder.0249 ↗
RezumatDate bibliografice

Rezumat

Background: Urothelial bladder cancer is a major health challenge owing to its high incidence, elevated mortality rates, and clinical diversity. Objective: This systematic review and meta-analysis assesses the efficacy of pembrolizumab in the treatment of non-muscle-invasive bladder cancer (NMIBC), muscle-invasive bladder cancer (MIBC), and metastatic urothelial carcinoma (mUC). After applying the inclusion and exclusion criteria, a literature search of PubMed, Scopus, and Web of Science (January 2020–June 2025) identified eight studies on NMIBC, MIBC, and mUC for the final analysis. Analysis revealed an advantage of pembrolizumab-based treatment (odds ratio [OR]: 1.86; 95% confidence interval [CI]: 1.70–2.03). Subgroup analyses showed the effectiveness in MIBC (OR: 1.88; 95% CI: 1.65–2.12) and mUC (OR: 1.94; 95% CI: 1.82–2.11). In contrast, the NMIBC subgroup lacked significance (OR: 1.28; 95% CI: 0.86–1.91), reflecting the evidence from small, early-phase studies. Pembrolizumab showed improved pathological complete response, progression-free survival, and disease-free survival in groups with elevated programmed death-ligand 1 expression and a high tumor mutational burden. Conclusion: Pembrolizumab is highly effective in treating MIBC and mUC; however, its impact on NMIBC remains uncertain. The limited number of studies and brief follow-up periods highlight the need for larger trials with long-term survival data.

Cunoștințe potrivite muncii dumneavoastră.

De la începutul gratuit și cercetarea bibliografică personală până la Research Suite complet.

Vezi tarifele →

Sunt incluse toate textele integrale ale editorilor?

Nu. Referințele bibliografice, rezumatele și textele integrale sunt conținuturi diferite. Disponibilitatea unui text integral depinde de sursă, de Open Access și de licențele pe care le aveți deja. Un abonament EUVIMED nu înlocuiește drepturile suplimentare ale editorilor.

Vezi tarifele →